麻豆传媒

Joanne Mortimer, MD, on a phase III trial adding abemaciclib to fulvestrant in the second line

"Striking differences," says researcher

Adriana Kahn, MD, highlights some of the exciting research in the metastatic setting

Jin Sun L. Bitar provides an overview of the ongoing neoHIP trial

Maryam Lustberg, MD, details three posters she was a discussant on at ASCO 2023

Those 65 and up had the same efficacy along with an "acceptable" increase in toxicity

Including CDK4/6 inhibitor with endocrine therapy improved invasive disease-free survival

Megan Kruse, MD, says we need to balance the efficacy and toxicity in a real-world setting

Lasofoxifene plus abemaciclib elicited encouraging PFS with an acceptable toxicity profile

Jane Meisel, MD, discusses the implications of the TROPiCS-02 study

Trastuzumab deruxtecan shows remarkable improvement in progression-free and overall survival

William Gradishar discusses the PALOMA-3 and MONALEESA-3 trials

Sayeh Lavasani discusses the latest updates from MONALEESA-3

A promising strategy for improving responses with checkpoint inhibition